Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:1764-1771
Published online before print September 3, 2009, doi: 10.1161/ATVBAHA.109.192609
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
29/11/1764    most recent
ATVBAHA.109.192609v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Zhang, Y.
Right arrow Articles by Galper, J. B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, Y.
Right arrow Articles by Galper, J. B.
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2009;29:1764.)
© 2009 American Heart Association, Inc.


Integrative Physiology/Experimental Medicine

Simvastatin Inhibits Angiotensin II-Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-Knockout Mice

Possible Role of ERK

Yali Zhang; Jack C. Naggar; C. Michael Welzig; Debbie Beasley; Karen S. Moulton; Ho-Jin Park; Jonas B. Galper

From the Molecular Cardiology Research Institute, Department of Medicine (Y.Z., J.C.N., D.B., H.-J.P., J.B.G.), Tufts Medical Center, Tufts University School of Medicine, Boston, Mass; the Department of Neurosciences (C.M.W.), Medical University of South Carolina, Charleston; the Cardiology Division (K.S.M.), University of Colorado Denver, Aurora.

Correspondence to Jonas B. Galper, Molecular Cardiology Research Institute, Box #8486, Tufts Medical Center, 750 Washington St, Boston, MA 02111. E-mail Jgalper{at}tuftsmedicalcenter.org

Objective— Abdominal aortic aneurysm (AAA) is a life-threatening disease affecting almost 10% of the population over age 65. Generation of AAAs by infusion of angiotensin (Ang) II in apolipoprotein E-knockout (ApoE–/–) mice is an animal model which supports an imbalance of the renin-angiotensin system in the pathogenesis of AAA. The effect of statins on AngII-mediated AAA formation and the associated neovascularization is not known. Here we determined the effect of simvastatin and the ERK inhibitor, CI1040, on AngII-stimulated AAA formation.

Methods and Results— ApoE–/– mice infused for 28 days with AngII using osmotic minipumps were treated with placebo, 10 mg/kg/d simvastatin, or 100 mg/kg/d CI1040. 95% of AngII-treated mice developed AAA with neovascularization of the lesion, increased ERK phosphorylation, MCP-1 secretion, and MMP activity. These effects were markedly reversed by simvastatin and in part by CI1040. Furthermore, simvastatin and the ERK inhibitor U0126 reversed AngII-stimulated angiogenesis and MMP secretion by human umbilical vein endothelial cells.

Conclusions— These data support the conclusion that simvastatin interferes with AAA formation induced by AngII in ApoE–/– mice at least in part via ERK inhibition.

Infusion of angiotensin (Ang) II in apolipoprotein E-knockout (ApoE–/–) mice is an animal model for abdominal aortic aneurysm (AAA). Our data support the conclusion that simvastatin interferes with AngII-stimulated AAA formation in these mice at least in part via the inhibition of ERK.


Key Words: angiotensin II • abdominal aortic aneurysm • statin • ERK inhibition • angiogenesis